Successful treatment of cyclic thrombocytopenia with thrombopoietin‐mimetic agents: A report of two patients

Abstract

American Journal of HematologyVolume 84, Issue 7 p. 459-461 LetterFree Access Successful treatment of cyclic thrombocytopenia with thrombopoietin-mimetic agents: A report of two patients† Prithviraj Bose, Prithviraj Bose Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OklahomaSearch for more papers by this authorKhader K. Hussein, Khader K. Hussein Central Oklahoma Cancer Center, Oklahoma City, OklahomaSearch for more papers by this authorDeirdra R. Terrell, Deirdra R. Terrell Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OklahomaSearch for more papers by this authorDietmar Berger, Dietmar Berger Amgen Inc., Thousand Oaks, CaliforniaSearch for more papers by this authorLawrence Rice, Lawrence Rice Department of Medicine, The Methodist Hospital, Weill Cornell Medical College, Houston, TexasSearch for more papers by this authorJames N. George, Corresponding Author James N. George [email protected] Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OklahomaThe University of Oklahoma Health Sciences Center, Room CHB 358, 801 NE 13th Street, Oklahoma City, OK 73104Search for more papers by this author Prithviraj Bose, Prithviraj Bose Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OklahomaSearch for more papers by this authorKhader K. Hussein, Khader K. Hussein Central Oklahoma Cancer Center, Oklahoma City, OklahomaSearch for more papers by this authorDeirdra R. Terrell, Deirdra R. Terrell Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OklahomaSearch for more papers by this authorDietmar Berger, Dietmar Berger Amgen Inc., Thousand Oaks, CaliforniaSearch for more papers by this authorLawrence Rice, Lawrence Rice Department of Medicine, The Methodist Hospital, Weill Cornell Medical College, Houston, TexasSearch for more papers by this authorJames N. George, Corresponding Author James N. George [email protected] Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OklahomaThe University of Oklahoma Health Sciences Center, Room CHB 358, 801 NE 13th Street, Oklahoma City, OK 73104Search for more papers by this author First published: 16 April 2009 https://doi.org/10.1002/ajh.21435Citations: 5 † Conflict of interest: Authors K.K.H., D.R.T., L.R., and J.N.G. have received research support from Amgen Inc.; J.N.G. and D.R.T. have served as consultants for Amgen Inc.; L.R. is a member of the Speakers' Bureau for Amgen and GlaxoSmithKline; and D.B. is an employee of Amgen. AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL References 1 Go RS. Idiopathic cyclic thrombocytopenia. Blood Rev 2004; 19: 53– 59. 2 Bussel JB,Cheng G,Saleh MN, et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med 2007; 357: 2237– 2347. 3 Kuter DJ,Bussel JB,Lyons RM, et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: A double-blind randomized controlled trial. Lancet 2008; 371: 395– 403. 4 George JN,Terrell DR. Novel thrombopoietic agents: A new era for patients with thrombocytopenia. Haematologica 2008; 93: 1445– 1449. 5 Kuter DJ. Thrombopoietin and thrombopoietin mimetics in the treatment of thrombocytopenia. Annu Rev Med 2009; 60: 193– 206. 6 Rice L,Nichol JL,McMillan R,Roskos LK,Bacile M. Cyclic immune thrombocytopenia responsive to thrombopoietic growth factor therapy. Amer J Hematol 2001; 68: 210– 214. 7 Bussel JB,Kuter DJ,Pullarkat V, et al. Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP. Blood 2009; 113: 2161– 2171. 8 Portielje JEA,Westendorp RGJ,Kluin-Nelemans HC,Brand A. Morbidity and mortality in adults with idiopathic thrombocytopenic purpura. Blood 2001; 97: 2549– 2554. 9 Hammond WP,Price TH,Souza LM,Dale DC. Treatment of cyclic neutropenia with granulocyte colony-stimulating factor. New Eng J Med 1989; 320: 1306– 1311. 10 Bonilla MA,Dale DC,Zeidler C, et al. Long-term safety of treatment with recombinant human granulocyte colony-stimulating factor (r-metHuG-CSF) in patients with severe congenital neutropenias. Br J Haematol 1994; 88: 723– 730. 11 Haurie C,Dale DC,Mackey MC. Cyclic neutropenia and other periodic hematological disorders: A review of mechanisms and mathematical models. Blood Rev 1998; 92: 2629– 2640. 12 Li JZ,Yang C,Xia YP, et al. Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood 2001; 98: 3241– 3248. Citing Literature Volume84, Issue7July 2009Pages 459-461 ReferencesRelatedInformation